Yet Another Watered-Down Health Reform Plan

18 September 1994

Whilst some are saying that US health care reform is dead for this year, others are still plugging away at getting something on the table, no matter how much original proposals have to be diluted.

The latest is Republican Senator Robert Dole, who has called on Congressional leaders (including himself, Senate Majority Leader George Mitchell, House Majority Leader Richard Gephardt and House Minority Whip Newt Gingrich) to work on a more limited version of health care reform- (which would include measures barring refusal of coverage for pre-existing conditions and setting up portability) - that could be vetoed by any of them before it goes to the floor of each House.

On "Face the Nation," Sen Dole said there are about 20 areas of agreement on reform, but for any reform to pass in the few weeks remaining, it would have to move under a leadership plan that could block all efforts to amend or filibuster. He noted that he could support only a plan that is scaled back further than that he proposed two months ago, which called for insurance market reforms and limited subsidies for poor Americans. That plan would cost more than his staff had calculated, according to the Congressional Budget Office.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight